Merck Pays $6.7B for Terns, Investors Question Premium Merck's $6.7B cash bid for Terns Pharma (Mar 25, 2026) implies an estimated 70–80% premium to recent trading, raising questions about valuation and integration timelines.

Merck Pays $6.7B for Terns, Investors Question Premium: Merck's $6.7B cash bid for Terns Pharma (Mar 25, 2026) implies an estimated 70–80% premium to recent trading, raising questions about valuation and… 👈 Read full analysis #Merck #TernsPharma #Pharmaceuticals #MergersAndAcquisitions #Investing